Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy

Human epidermal growth factor receptor 2 (HER2) regulates cell mitosis, proliferation, and apoptosis. Trastuzumab is a HER2-targeted monoclonal antibody (mAB), which can prolong the overall survival rate of patients with HER2 overexpression in later periods of gastric cancer and breast cancer. Altho...

Full description

Bibliographic Details
Main Authors:	Fan Shi, Yanli Liu, Xuexiao Zhou, Pei Shen, Ran Xue, Min Zhang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Series:	Drug Delivery
Subjects:	Antibody-drug conjugates human epidermal growth factor receptor 2 disitamab vedotin trastuzumab emtansine trastuzumab deruxtecan
Online Access:	https://www.tandfonline.com/doi/10.1080/10717544.2022.2069883

Similar Items

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)

Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review
by: Yanfang Lan, et al.
Published: (2024-06-01)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
by: Linehan AS, et al.
Published: (2021-02-01)

Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review
by: Xiangjun Qi, et al.
Published: (2022-09-01)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
by: Jeffrey V. Leyton
Published: (2020-07-01)

The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
by: Haijun Huang, et al.
Published: (2023-04-01)

Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression
by: Meiling Lan, et al.
Published: (2024-12-01)

Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study
by: Jiayu Wang, et al.
Published: (2024-07-01)

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)

Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance
by: Claudiu Morgovan, et al.
Published: (2024-04-01)

Fam-trastuzumab deruxtecan-nxki (Enhertu®): A narrative drug review
by: Ryan Varghese, et al.
Published: (2022-01-01)

Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget’s disease with Her-2 overexpression
by: Jia-Ling Wang, et al.
Published: (2024-06-01)

Enhanced Characterization of Lysine-Linked Antibody Drug Conjugates Enabled by Middle-Down Mass Spectrometry and Higher-Energy Collisional Dissociation-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation and Ultraviolet Photodissociation
by: Eleanor Watts, et al.
Published: (2024-04-01)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
by: Eun-Jeong Jeon, et al.
Published: (2023-02-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Plasma Exchange May Enhance Antitumor Effects by Removal of Soluble Programmed Death-Ligand 1 and Extracellular Vesicles: Preliminary Study
by: Kazumasa Oya, et al.
Published: (2022-10-01)

Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review
by: Yang Li, et al.
Published: (2023-11-01)

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2024-02-01)

Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study
by: Miao He, et al.
Published: (2024-04-01)

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
by: Mary Anne Fenton, et al.
Published: (2023-11-01)

Efficacy and safety of trastuzumab deruxtecan therapy
by: Nina Privšek, et al.
Published: (2024-12-01)

Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
by: Zhao Luping, et al.
Published: (2025-01-01)

Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report
by: Weiping Li, et al.
Published: (2024-09-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
by: Jianxin Chen, et al.
Published: (2025-02-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer
by: Chuanao Zhang, et al.
Published: (2025-02-01)

Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
by: Marion Lepelley, et al.
Published: (2018-11-01)

Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study
by: Fei Qu, et al.
Published: (2024-11-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
by: Kyoko Gocho, et al.
Published: (2022-04-01)

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
by: Oğuzcan Kınıkoğlu, et al.
Published: (2024-06-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016-01-01)

Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure
by: A. Falcón González, et al.
Published: (2021-01-01)